Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(60%)
Results Posted
300%(3 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
3
60%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)

Detailed Status

Active, not recruiting3
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

completed120%
terminated120%
active_not_recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
active_not_recruitingphase_2

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672
active_not_recruitingphase_2

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

NCT04941287
active_not_recruitingphase_2

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

NCT03688178
completedphase_1

A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma

NCT03307746
terminatedphase_1

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

NCT02924038

Clinical Trials (5)

Showing 5 of 5 trials
NCT03038672Phase 2

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Active Not Recruiting
NCT04941287Phase 2

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Active Not Recruiting
NCT03688178Phase 2

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active Not Recruiting
NCT03307746Phase 1

A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma

Completed
NCT02924038Phase 1

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5